Search | Clinical Trials Finder

Conditions: Prostate Cancer Recurrent, Solid Tumor, Adult
Interventions: Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib; Combination Product
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Oligometastases
Interventions: Nelfinavir, Stereotactic Body Radiation (SBRT); Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection, Hepatitis C
Interventions: nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 42
States / cities: Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 22 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more

Conditions: HIV Infections, Pregnancy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Delavirdine mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 0 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 0 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
Interventions: Laboratory Biomarker Analysis, Nelfinavir Mesylate; Other · Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 44
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab; Drug · Radiation · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery; Procedure · Drug · Other + 2 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 1 Day to 13 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nelfinavir; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cardiopulmonary Bypass
Interventions: Nelfinavir/placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

Stereotactic Body Radiation With Nelfinavir for Oligometastases

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

A Study of HIV Levels During Pregnancy and After Childbirth

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection